CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
伴中枢神经系统受累的复发/难治性多发性骨髓瘤经 Elranatamab 成功治疗：首例报告
英文原题：Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case.
查看英文原题
Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
多发性骨髓瘤（MM）累及中枢神经系统（CNS）是一种罕见且棘手的并发症，预后不佳、治疗选择有限。双特异性抗体（bsAb）和CAR-T 细胞等新兴T细胞导向疗法治疗MM已取得显著成功，但其对CNS受累的疗效尚不明确。Elranatamab是一种人源化双特异性抗体，可靶向B细胞成熟抗原（BCMA）并结合表达CD3的T细胞，在复发/难治性MM中已显示良好疗效，但此前尚无其治疗CNS-MM的报告。本文报告一例37岁男性MM患者伴CNS受累，经Elranatamab治疗后获得成功。
展开英文摘要原文
Central nervous system (CNS) involvement in multiple myeloma (MM) is a rare and challenging complication associated with poor prognosis and limited treatment options. Emerging T-cell directing therapies, such as bispecific antibodies (bsAbs) and chimeric antigen receptor T cells (CAR-T), have shown remarkable success in treating MM, but their efficacy in CNS involvement remains unclear.
Elranatamab, a humanized bispecific antibody targeting B-cell maturation antigen (BCMA) and CD3-expressing T cells, has demonstrated promising results in relapsed refractory MM.
However, its efficacy in treating CNS-MM has not been reported.
We present a case of a 37-year-old male MM patient with CNS involvement who has been successfully treated with Elranatamab.
论文信息
- 作者
- Mutlu YG、Yıgıt Kaya S、Maral S、Melek E、Baslar Z、Kaynar L、Sevindik OG
- 单位
- Department of Hematology, Istanbul Medipol University, Istanbul, Türkiye.Turkey
- 文献类型
- 病例报告
- 期刊
- Frontiers in immunology2023
- 原文标识
- PubMed 37901215 · DOI 10.3389/fimmu.2023.1276295
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →